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1. Introduction
Stability indicating methods have become an 
important aspect of any analytical method validation 
and  a  part  of  US  FDA  requirements1.  Chemically, 
Eprosartan is designated as 4-({2-butyl-5-[2-carboxy-
2-(thiophen-2-ylmethyl)  eth-1-en-1-yl]-1H-imidazol-
1-yl}  methyl)  benzoic  acid  (Fig.  1)  is  a  new 
antihypertensive  drug,  the  drug  acts  on  the  renin-
angiotensin  system  in  two  ways  to  decrease  total 
peripheral  resistance.  First,  it  blocks  the  binding  of 
angiotensin  II  to  AT1 receptors  in  vascular  smooth 
muscle, causing vascular dilatation. Second, it inhibits 
sympathetic  norepinephrine  production,  further 
reducing  blood  pressure2,3.  Very  few  methods 
appeared  in  the  literature  in  the  spectrophotometric 
determination of Eprosartan4,5,6.  Therefore,  we have 
made an attempt to develop a new, simple, accurate 
stability  indicating  RP-HPLC  method  for  the 
determination of Eprosartan in pure and tablet forms. 
The  proposed  method  was  validated  as  per  ICH 
guidelines Q2A7.
Fig.1 chemical structure of Eprosartan.
2. Experimental
2.1 Chemicals and Instrumentation: Eprosartan was 
supplied by ABS LIFE SCIENCE LTD.  and tablets 
(Label  Claim:  400  mg  per  tablet,  Product  Name: 
EPROZAR  and  Manufacturer:  INTAS 
Pharmaceuticals  was  procured  from  the  market. 
Methanol,  Acetonitrile  and  Potassium  dihydrogen 
orthophosphate AR Grade, Orthophosphoric acid LR 
Grade were purchased from RFCL Ltd., New Delhi, 
India.  High  purity  water  was  prepared  by  using 
Millipore Milli-Q plus water purification system.
The HPLC used was a shimazdu HPLC LC-
20AT  series  with  SPD-20A  UV  photodiode  array 
detector and LCsolution software, Japan was used for 
all  the experiments.  The column used was XTerra® 
RP18, 250 x 4.6 mm, 5 µ (water, Ireland) and Luna C8 
(Octylsilane),  250  x  4.6  mm,  5  µ  (Phenomenax, 
USA). Thermal Stability studies were performed in 
a  dry  air  oven  (Thermo  labs,  India).  Micrositer 
syringer- 50 µL (Hamilton Company, USA). 
2.2 Chromatographic conditions: Chromatographic 
separation was achieved at ambient temperature on a 
reversed  phase  column  using  a  mobile-phase 
consisting  of  a  mixture  of  Methanol:  Acetonitrile: 
Buffer  solution  (Dissolve  0.02  M  potassium  di-
hydrogen  orthophosphate  in  water.  Adjust  pH  of 
solution to 6.85 ± 0.05 with orthophosphoric acid) in 
the  ratio  (45:45:10).  The  mobile  phase  so  prepared 
was filtered through 0.22 µm nylon membrane filter 
and degassed by sonication. Flow rate of 1 mL / min 
was maintained. Detection was carried out at 232 nm. 
The  injection  volume  was  20  µL  for  assay  and 
degradation level.
2.3  Standard  preparation:  100  mg  of  Eprosartan 
working  standard  was  accurately  weighed  and 
transferred to a 100 mL volumetric flask. Solution was 
sonicated  and  diluted  up  to  the  mark  with  mobile 
phase.  A  series  of  standard  solutions  in  the 
concentration  range  of  20,  40,  60,  80,  100  and 
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120µg/ml  were  prepared  followed  by  a  suitable 
dilution of stock solution with the mobile phase. 
2.4 Sample preparation: 20  tablets  were  weighed 
and finely powdered.  Blend equivalent to 50 mg of 
Eprosartan  was  transferred  to  a  100 mL volumetric 
flask. About 60 mL of mobile phase was added and 
the solution was sonicated for 15 min and make up to 
the mark  with  mobile  phase.  The resulting  solution 
was filtered through 0.22µm nylon membrane filter. 
The solution was mixed well and centrifuged at 2500 
RPM for 10 min.
2.5 Preparation of calibration graph:  The linearity 
of  response  for  Eprosartan  assay  method  was 
determined by preparing and injecting solutions with 
concentrations of about 2, 4, 6, 8, 10 and 12µg/ml of 
Eprosartan. 
2.6 Method validation:
2.6.1 Precision: Precision was measured in terms of 
repeatability  of  application  and  measurement. 
Repeatability of standard application was carried out 
using six replicates of the same standard concentration 
(6 µg / mL for standard application). Repeatability of 
sample measurement was carried out in six different 
sample preparations from same homogenous blend of 
marketed sample (6 µg /mL for sample application). It  
showed  very  low % relative  standard  deviation  (% 
RSD) of peak area of Eprosartan. 
2.6.2 Accuracy: Accuracy  (Recovery)  study  was 
performed by spiking 30, 50 and 70% of Eprosartan 
working  standard  to  a  preanalysed  sample.  The 
preanalysed sample was weighed in such a way that 
final  concentration  is  half  or  50%  of  the  sample 
preparation before spiking. The percentage sum level 
of  preanalysed  sample  and  spiked  amount  of  drug 
should  be  80,  100  and  120% of  simulated  dosages 
nominal or target concentration of sample preparation. 
The accuracy of the analytical method was established 
in  duplicate  across  its  range  according  to  the  assay 
procedure.
% Recovery = 
 
100
%
covRe%
×
SumLevel
eredAmount
2.6.3 Ruggedness and robustness: Method 
robustness  and  ruggedness  was  determined  by 
analysing same sample at normal operating conditions 
and  also  by  changing  some  operating  analytical 
conditions  such  as  column  make,  mobile  phase 
composition,  flow rate,  instrument  and  analyst.  The 
robustness  and  ruggedness  of  the  method  was 
established as the % deviation from mean assay value 
obtain from precision study is less than ±2.0%.
2.7  Analysis  of  marketed  formulation:  20  tablets 
were  weighed  and  finely  powdered.  Transfer  blend 
equivalent  to  100  mg  of  Eprosartan  to  a  100  mL 
volumetric flask. Add about 60 mL of mobile phase 
and sonicate  for  15 min and make up volume with 
mobile phase. Mix well and centrifuge the solution at 
2500 RPM for 10 min. Dilute the solution up to the 
desired  concentration  and  inject  it  into  the  HPLC 
system.
2.8 Forced Degradation Studies: 
2.8.1  Preparation  of  acid  and  based-  induced 
degradation  product:  Tablet  powder  equivalent  to 
100  mg  of  Eprosartan  was  transferred  to  100  mL 
volumetric flask. To it, 10 mL of mobile phase was 
added  and  sonicated  for  15  min  with  intermittent 
shaking. To it 5 mL of 1 N HCl was added and 5 mL 
of 1 N NaOH were added separately. The sample was 
heated on a boiling water bath for 30 min, cooled to 
room temperature and diluted to volume with mobile 
phase, mixed well. The acidic forced degradation and 
the alkaline forced degradation was performed in dark 
in order to exclude the possible degradative effect of 
light. This solution was centrifuged at 2500 rpm for 
10 min and 5 mL of supernatant liquid was transferred 
to  25  mL volumetric  flask,  diluted  to  volume with 
mobile phase, mixed well and injected into the HPLC 
system. 
2.8.2 Preparation of hydrogen peroxide - induced 
degradation  product:  Tablet  powder  equivalent  to 
100  mg  of  Eprosartan  was  transferred  to  100  mL 
volumetric flask. To it, 10 mL of mobile phase was 
added  and  sonicated  for  15  min  with  intermittent 
shaking. To it 5 mL of 3.0% H2O2 was added. The 
sample was heated on a boiling water bath for 30 min, 
cooled  to  room  temperature  and  diluted  to  volume 
with  mobile  phase,  mixed  well.  This  solution  was 
centrifuged  at  2500  rpm  for  10  min  and  5  mL of 
supernatant  liquid  was  transferred  to  25  mL 
volumetric flask, diluted to volume with mobile phase, 
mixed well and injected into the HPLC system. 
2.8.3  Photo-degradation  product:  Tablet  powder 
equivalent to 100 mg of Eprosartan (previously kept 
in  UV light  for  24  hr)  was  transferred  to  100  mL 
volumetric flask. To it, 10 mL of mobile phase was 
added  and  sonicated  for  15  min  with  intermittent 
shaking and diluted up to the mark with mobile phase. 
This solution was centrifuged at 2500 rpm for 10 min 
and 5 mL of supernatant liquid was transferred to 25 
mL volumetric flask, diluted to volume with mobile 
phase, mixed well and injected into the HPLC system. 
2.8.4 Thermal degradation product:  Tablet powder 
equivalent to 100 mg of Eprosartan was transferred to 
100  mL volumetric  flask.  To  it,  10  mL of  mobile 
phase  was  added  and  sonicated  for  15  min  with 
intermittent  shaking.  The  sample  was  heated  on  a 
boiling  water  bath  for  30  min,  cooled  to  room 
temperature and diluted to volume with mobile phase, 
mixed well. This solution was centrifuged at 2500 rpm 
for  10  min  and  5  mL  of  supernatant  liquid  was 
transferred  to  25  mL  volumetric  flask,  diluted  to 
volume with mobile  phase,  mixed well  and injected 
into the HPLC. The specificity degradation study data 
for the determination of Eprosartan and its degradants 
in pharmaceutical dosage form is given in Table 5 & 
Table 6. The no stress treatment sample (as control) 
has  been  evaluated  relative  to  the  standard 
concentration where as rest of the stressed condition 
samples (Figs. 2-8) is evaluated relative to the control 
sample  with  respect  to  the  %  assay  and  % 
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degradation.  The  percentage  degradation  results  are 
calculated by area normalization method.
Fig. 2 Chromatogram of standard Eprosartan.
Fig. 3 Chromatogram of test Eprosartan.
Fig. 4 Chromatogram of acid degraded sample.
Fig.5 Chromatogram of alkali degraded sample.
Fig. 6 Chromatogram of Hydrogen Peroxide degraded 
sample.
Fig. 7 Chromatogram of UV degraded sample.
Fig. 8 Chromatogram of Thermal degraded sample.
2.9 Detection of the related impurities:  Weigh and 
finely powder not less than 20 tablets. Transfer blend 
equivalent  to  50  mg  of  Eprosartan  to  a  50  mL 
volumetric flask. Add about 30 mL of mobile phase 
and  sonicate  for  20 min and make up volume with 
mobile phase. Mix well and centrifuge the solution at 
2500 rpm for 10 min. The clear supernatant solution 
was injected into the HPLC system.
3. Results and discussion
3.1  Method of  development:  The  chromatographic 
conditions were optimized with a view to develop a 
stability-  indicating  assay  method.  Two  different 
columns  were  tried  as  under  chromatographic 
conditions namely, XTerra® RP18, 250 x 4.6 mm, 5 µ 
(water, Ireland) and Luna C8 (Octylsilane), 250 x 4.6 
mm, 5 µ (Phenomenax, USA).  Luna C8 gave good 
peak shape but a lower retention with low peak purity. 
XTerra® RP18 column had given a good peak shape 
with response at affordable retention time with peak 
purity  of  Eprosartan  on  higher  side.  The 
chromatographic  conditions  finally  comprised  of  a 
mobile-phase  in  the ratio  of  Methanol:  Acetonitrile: 
Buffer  solution  (Dissolve  0.02  M  potassium 
dihydrogen  orthophosphate  in  water.  Adjust  pH  of 
solution to 6.85 ± 0.05 with ortho-phosphoric acid) in 
the ratio (45:45:10) at a flow rate of 1 mL / min using 
XTerra® RP18 column;  250 x 4.6 mm; 5 µ (G.  L. 
Sciences, Japan) at 232 nm. 
3.2 Calibration curve: These results indicate that the 
response is linear over the range of 20, 40, 60, 80, 100 
and  120µg/ml  of  Eprosartan  with  coefficient  of 
regression, R2, value as 0.9998 as shown in Table 1. 
The  value  of  correlation  coefficient,  slope  and 
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intercept  were  0.9998,  1661.8,  and  114.82 
respectively.
3.3 Method validation : 
3.3.1  Precision:  The  %RSD  for  repeatability  of 
sample  preparation  is  0.95%.  This  shows  that 
precision of the method is satisfactory as % relative 
standard deviation is not more than ± 2.0%. Table 2 
represent the precision of method. 
3.3.2  Ruggedness  and  Robustness:  Method 
robustness  and  ruggedness  was  determined  by 
analysing same sample at normal operating conditions 
and  also  by  changing  some  operating  analytical 
conditions  such  as  column  make,  mobile  phase 
composition,  flow rate,  instrument  and  analyst.  The 
deliberate aforementioned changes in parameters alter 
the result  of  Eprosartan  0.03% to  method precision 
study,  which  is  not  a  significant  change.  The 
robustness  and  ruggedness  of  the  method  is 
established as the % deviation from mean assay value 
obtain from precision study is less than ±2.0%. Table 
3  represent  the  ruggedness  and  robustness  of  the 
method.
3.3.3  Accuracy:  The  accuracy  of  the  method  was 
established by recovery studies. Results indicate that 
the  individual  recovery  of  Eprosartan  ranges  from 
100.41% to 101.54% with mean recovery of 100.75% 
and  %  relative  standard  deviation  of  0.41%.  The 
recovery  of  Eprosartan  by  proposed  method  is 
satisfactory  as  %  relative  standard  deviation  is  not 
more than ± 2.0% and mean recovery between 98.0 - 
102.0%. Table 4 represent the accuracy of method. 
3.4 Analysis of the marketed formulation: The drug 
content  was found to be 98.02% with a % RSD of 
0.95%. It was noted that no degradation of Eprosartan 
had occurred  in the marketed  formulation that  were 
analysed  by  this  method.  The  low  RSD  value 
indicated  the  suitability  of  this  method  for  routine 
analysis of Eprosartan in pharmaceutical dosage form. 
3.5 Stability- Indicating property: The stress studies 
were conducted and the data were depicted in (Table 
5).  The  chromatogram  of  no  stress  treatment  of 
control and sample showed no additional peaks (Figs. 
2,3).  The  chromatogram  of  acid  degraded  sample 
showed  additional  peaks  at  retention  time  (RT)  of 
4.00,  4.78  and  5.95  min,  respectively  Fig.4.  The 
chromatogram  of  alkali  degraded  sample  showed 
additional  peaks  at  RT  of  4.34  min  and  5.86  min, 
respectively Fig.  5.  The chromatogram of  hydrogen 
peroxide degraded sample showed additional peaks at 
RT of 3.32, 4.83 and 5.96 min respectively Fig. 6. The 
chromatogram  of  UV  degraded  sample  showed 
additional  peaks at  RT of  4.74,  5.94 and 6.47 min, 
respectively  Fig.  7.  The  chromatogram  of  thermal 
degraded sample showed additional peak at RT of 4.7 
min Fig.  8. Rest of the peaks,  if any,  were from its 
blank or placebo in each of these specified conditions. 
In each forced degradation samples where additional 
peaks  were  observed,  the  response  of  the  drug  was 
changing  from  the  initial  control  sample.  This 
indicates  that  the  drug  is  susceptible  to  acid-base 
hydrolysis  degradation,  hydrogen  peroxide 
degradation, UV degradation and thermal degradation. 
The lower RT of the degraded component indicated 
that they were more polar than the analyte itself. 
3.6 Detection of the related impurities:  The sample 
solution  showed  no  additional  peak  other  than 
principal  peak.  Hence,  related  impurities  are  not 
present in the market sample. 
Table 1 : Regression characteristics of the proposed 
HPLC method
S. No Drug Eprosartan
1 Range (µg/ml) 20-120µg/ml
2 Detection wavelength (l max) 232 nm
3 Mean ‘R2’ value 0.9998
4 Slope (m) 1661.8
5 Intercept (c) 114.82
6 Run time 10 min
7 Retention Time (min) 7.1
8 Theoretical Plates (N) 3276
9 Tailing Factor 1.02
Table 2 : Method precision of Eprosartan
Sample 
Preparation
% Assay 
Eprosartan
% Deviation From Mean 
Assay value Eprosartan
1 99.79 1.77
2 97.86 -0.16
3 98.04 0.02
4 97.26 -0.76
5 97.26 -0.76
6 97.92 -0.10
Mean ±SD 98.02 ±0.93
%RSD 0.95
Table 3 : Ruggedness and robustness of Eprosartan
Parameter Normal (Original) Changed conditions
Column make
X Terra® RP18 
column; 250 x 4.6 
mm; 5 µ
Luna C8 (Octylsilane), 
250 x 4.6 mm; 5 µ
Flow rate 1 mL/min 1.2 mL/min
Mobile phase
Composition
(pH 6.85) Methanol: 
Acetonitrile: Buffer
(KH2PO4) (45:35:20)
(pH 6.50) Methanol: 
Acetonitrile: Buffer
(KH2PO4) (40:40:20)
Pump
Jasco PU-2080 plus 
series
Shimazdu LC-20AT
Detector
Jasco UV-2075 plus 
series
Shimazdu UV-VIS 
detector
% assay of 
Eprosartan
98.02% 98.05%
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Table 4 : Recovery studies of Eprosartan
Sample 
preparation
% simulated 
dosage 
normal
% sum 
level
% 
amount 
recovered
% 
recovery
Preanalysed 
sample 99.02
1 80 80.46 81.18 100.90
2 80 79.98 81.19 101.52
1 100 100.90 101.52 100.61
2 100 101.08 101.50 100.41
1 120 121.24 121.85 100.50
2 120 121.04 121.70 100.54
Mean 100.75
± Standard deviation 0.41
% Relative standard deviation 0.41
Table 5 : Stressed Study Data of Eprosartan.
S. No Condition % assay Eprosartan
Retention 
time of drug
% 
Degradation
1 No stress treatment 98.02 6.984 Nil
2 Acid 99.19 4, 4.78, 5.95 0.09
3 Alkali 99.77 4.34, 5.86 0.07
4 H202 98.32
3.32, 4.83, 
5.96 0.05
5 UV 99.22 4.74, 5.94, 6.47 0.49
6 Thermal 99.07 4.70 0.03
Table 6 : Summaries of Forced Degradation Results:
S. No Stress condition Time % Assay ofactive substance
Mass balance 
(%assay + % 
degradation products)
Remarks
1 Acid degradation (1 N HCl) 1/2 hr 99.76 99.4
No degradation 
products formed
2 Alkali degradation (1 N NaOH) 1/2 hr 99.88 99.3
No degradation 
products formed
3 H2O2 degradation (3%) 1/2 hr 97.64 98.1
Mild degradation 
formed
4 UV degradation 24 hr 99.44 99.2 No degradation products formed
5 Thermal degradation (60 0C) 1/2 hr 99.45 99.5
No degradation 
products formed
4. Conclusions 
The  developed  HPLC  technique  is  precise, 
specific,  accurate  and  stability  indicating.  Statistical 
analysis  proves  that  the method is reproducible  and 
selective  for  the  analysis  of  Eprosartan  in 
pharmaceutical dosage form. The method can be used 
to  determine  the  purity  of  the  drug  available  from 
various  sources.  As  the  method  separates  the  drug 
from its degradation products, it can be employed as a 
stability indicating one.
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